Preclinical Oncology CRO Services | Clinical Trial Specialty Testing

The most clinically annotated, molecularly-characterized bank of over 1,400 solid tumor and hematological models
A growing bank of over 100 multi-omic characterized cell line-derived xenograft mouse models
Characterized syngeneic and humanized mouse models for testing innovative immune-oncology therapeutics across multiple mechanisms of action

SOLID TUMOR PDX MODELS

Over 1,400 clinically relevant TumorGraft^® models with correlation to clinical outcomes

HEMATOLOGICAL MODELS

A unique collection of primary never-passaged patient samples, accurately mirroring the heterogeneity of hematologic malignancies

SYNGENEIC MODELS

A collection of murine models across multiple indications, with a complete and functional mouse immune system

CDX MODELS

Over 100 cell-line derived xenograft mouse models to determine the efficacy of therapeutics

HUMANIZED MODELS

A diverse portfolio of Champions' ImmunoGraft^® to assess the effect of therapeutics on functional components of the human immune system

Novel, high-throughput screening platforms to deliver insights and derisk preclinical programs
Unique assays to assess mechanisms including cytotoxicity, proliferation, and infiltration
Coupled with multiple readouts to validate targets or screen various cancer indications

HEMATOLOGICAL VITROSCREEN

Test therapeutics in over 80 highly characterized primary, never-passaged hematological models from AML, ALL, CLL, MCL, and MM patients

TUMORGRAFT3D PLATFORM

Evaluate therapeutic efficacy in Champions' matrix-free, multiclonal 3D ex-vivo culture established from superior PDX models

CO-CULTURE ASSAYS

Assess the effect therapeutic agents have on cancer cells and the immune system in the tumor microenvironment

Unrivaled expertise in study design and execution, sample logistics and processing, and data analysis of clinical samples
Validated and fully customizable assays and collection kits for each analysis
Optimum flexibility and operational readiness in each clinical assay and sample type to help you accomplish more with each test

QUALITY ASSURANCE

Champions is GCLP-compliant for all clinical research platforms. CLIA accreditation is available on specific lab tests.

HIGH COMPLEXITY FLOW CYTOMETRY

High-quality, complex computational results with the ability to interrogate up to 30 parameters on each individual cell simultaneously within each patient sample.

LUMINEX & ELISA

Assess secreted protein levels longitudinally in clinical trials by mutiplex panel Luminex or custom-developed ELISA.

HISTOLOGY & IMMUNOHISTOCHEMISTRY

Evaluate target expression and assess morphological changes within patient tissues of interest.

NEXT GENERATION SEQUENCING

Determine patient segmentation and personalized medicine approaches based on bioinformatic and computational insights.

SAMPLE COLLECTION KITS & LOGISTICS

Tube and reagent types are customizable and streamlined to ensure collection kits are delivered to each clinical site prior to SIV.

What is the TumorGraft3D platform?

TumorGraft3D is a proprietary next-generation in vitro screening platform comprising over 1,400 multiclonal 3D tumor cultures derived from Champion's unparalleled bank of deeply characterized, clinically relevant patient-derived (PDX) tumor models. The 3D organoid models emulate molecular traits of the parent PDX models maintaining key cancer characteristics, gene expression profiles, and patients' pretreatment clinical responses.

The assay employs a unique matrix-free system with indication-specific media, ensuring the formation, maintenance, and retention of key cancer molecular characteristics without interfering with the drug.

Is the TumorGraft3D Platform Ex Vivo or In Vivo?

The TumorGraft3D platform is an ex vivo assay featuring 3D tumor models that precisely replicate the tumor microenvironment, capturing biological relevance, molecular heterogeneity, and patient diversity.

This enables scientists to advance their therapeutic pipeline from the ex vivo to the in vivo development stage with reliable data and confidence.

What sets TumorGraft3D models apart from other cell-based platforms?

Champions' TumorGraft3D platform allows for a direct generation of models from Champions' proprietary bank of PDX tumors, ensuring a high level of clinical relevance. This platform is compatible with high-throughput screening and a diverse portfolio of endpoint assays, enabling the generation of maximum insights within short timelines, cost-effectively. Specific cell component contributions can be precisely investigated, providing deeper insights into tumor biology and aiding in the development of targeted therapies.

Other cell-based assays are derived from a single-cell clone that lack heterogeneity and fail to replicate the tumor microenvironment (TME), leading to experimental inconsistency. These cells immortalized after multiple passages, diverge genetically from the original tumor cells, limiting their ability to generate reliable data for further reproducible research outcomes.

How do I initiate a TumorGraft3D study with Champions?

There are many aspects to planning and executing a successful ex vivo study. Champions works with you every step of the way to ensure you select the best models to test your hypothesis and choose endpoints that will lead to unparalleled insights driving decision-making. Our scientists collaborate with you throughout the project to ensure reliable research outcomes, facilitating a smooth and confident transition from ex vivo to subsequent in vivo studies.

Preclinical Oncology Services

An unparalleled portfolio of oncology CRO services and clinical specialty testing solutions to accelerate drug development

In Vivo Oncology Models